Resverlogix Corp. has a unique business model whereby we seek discovery and preclinical partnerships to advance our products. Our cutting edge technologies are well positioned in the largest commercial market segment of the life science industry.

We are currently in discussions with several leading life science organizations for our leading cardiovascular technology program NexVas PR. As a leader in the enhancement of ApoA-I, Resverlogix offers its future partners access to a breadth of intellectual property for unique small molecules for cardiovascular disease, cancer and fibrotic diseases.

We look forward to the opportunity to work with you.